Long-term use of interferon-β in multiple sclerosis increases Vδ1^-Vδ2^-Vγ9^- γδ T cells that are associated with a better outcome.

ABSTRACT:

Background

We previously reported that Vδ2⁺Vγ9⁺ γδ T cells were significantly decreased in multiple sclerosis (MS) patients without disease-modifying therapies (untreated MS) and were negatively correlated with Expanded Disability Status Scale (EDSS) scores, suggesting protective roles of Vδ2⁺Vγ9⁺ γδ T cells. Interferon-β (IFN-β) is one of the first-line disease-modifying drugs for MS. However, no previous studies have reported changes in γδ T cell subsets under IFN-β treatment. Therefore, we aimed to clarify the effects of the long-term usage of IFN-β on γδ T cell subsets in MS patients.

Methods

Comprehensive flow cytometric immunophenotyping was performed in 35 untreated MS and 21 MS patients on IFN-β for more than 2 years (IFN-β

SUBMITTER: Maimaitijiang G 

PROVIDER: S-EPMC6743159 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature